MCC
RVNC

Money Concepts Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Money Concepts Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,150
Closed -$39.7K – 3034
2022
Q4 		$39.7K Buy
+2,150
New +$49.2K ﹤0.01% 1337

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Money Concepts Capital's RVNC Position: Q1 2023 in Review

Money Concepts Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 2,150 shares — an estimated $39.7K sold.

Money Concepts Capital first reported a position in RVNC in Q4 2022 and held it in 1 quarter. The position peaked at $39.7K in Q4 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

  • Money Concepts Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 2,150 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $39.7K.
  • Money Concepts Capital first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 1 quarter.
  • Money Concepts Capital's Revance Therapeutics, Inc. position peaked at $39.7K in Q4 2022.
  • 216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.